ACADIA Pharmaceuticals downgraded by Guggenheim with a new price target
$ACAD
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim downgraded ACADIA Pharmaceuticals from Buy to Neutral and set a new price target of $20.00 from $23.00 previously